Will Tylenol maintain its U.S. OTC analgesics market share leadership through Q2 2026?

Tylenol has achieved 12 consecutive quarters of U.S. market share gains — this is an exceptionally strong track record. The analysis confirms private label penetration is DECLINING in Kenvue categories, which is highly unusual in consumer staples and directly supports continued brand leadership. The moat mapper rated COMPETITIVE_POSITION as DEFENSIBLE with HIGH confidence and 6/6 lens agreement. For Tylenol to lose #1 branded position, there would need to be a dramatic shift in consumer behavior. Even litigation headlines have not affected Tylenol's share trajectory historically.

Brand leadership in OTC analgesics is highly persistent. Tylenol's position reflects decades of brand equity, distribution strength, and consumer habit. The 12-quarter share gain streak suggests accelerating, not decelerating, competitive strength. The main risk scenario — litigation-driven consumer switching — would require not just negative headlines but a fundamental change in consumer trust, which historically takes years to manifest in share data even when it does occur (see J&J talc powder). 85% probability, with slight discount for unknown H2 2025 competitive dynamics.

The question asks about maintaining #1 BRANDED position through Q2 2026 — this is the next 3-4 months. Market share leadership in established OTC categories almost never shifts in a single quarter absent a product recall or safety event. Private label is the main competitive threat in OTC, and private label penetration is declining. The acetaminophen litigation has been ongoing for years without affecting share. New management's portfolio rationalization focuses on the top 41 brands, which strongly includes Tylenol. Very high probability of maintaining leadership.

This is a very high-probability YES. Tylenol's brand dominance in U.S. OTC analgesics is deeply entrenched. 12 consecutive quarters of gains. Private label declining. No credible branded competitor is positioned to overtake in 3-4 months. Even Advil (ibuprofen-based) is a different mechanism category. The only scenario for NO is a completely unexpected event like an FDA warning or major recall, which has no evidence basis. 90% probability.

Market share leadership positions in mature OTC categories are remarkably stable. Tylenol has been gaining share, not losing it. The question would only resolve NO under an extreme scenario: FDA label change, product recall, or a dramatic competitor launch. None of these are indicated by the analysis. The litigation has been proceeding for years without share impact. 87% probability of maintaining leadership through Q2 2026.

Strong probability of YES. The analysis provides overwhelming evidence of brand strength (6/6 lenses agree). Private label decline is a tailwind. The short timeframe (Q2 2026) makes a share leadership change nearly impossible absent an exogenous shock. The committee's brand-vs-organization paradox finding actually supports this — brands are winning even while the organization struggles, demonstrating brand resilience independent of organizational performance.

12 consecutive quarters of gains, private label declining, DEFENSIBLE competitive position. Market share leadership in OTC analgesics is deeply stable. Very high probability of maintaining through Q2 2026.

Brand leadership in mature OTC categories rarely shifts. Tylenol gaining share and private label declining. Would require an extreme event (recall, FDA warning) to lose #1 position in 3-4 months. 85% probability.

Highly likely YES. Strong brand momentum, declining private label competition, short timeframe. Only an exogenous shock could alter leadership position within Q2 2026. 88% probability.